Peptide questions · Retatrutide
Retatrutide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for retatrutide are nausea, vomiting and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: In the Phase 2 obesity trial (Jastreboff et al., NEJM 2023), the most common adverse events were gastrointestinal: dose-related, mostly mild to moderate, concentrated during dose escalation and partly eased by a 2 mg rather than a 4 mg start (nausea in up to 60% of people in the 8 mg arm that started at 4 mg and 45% at 12 mg, plus vomiting, diarrhea and constipation).
What is commonly reported with retatrutide
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Fatigue
- Abdominal pain
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Liraglutide and 17 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Liraglutide and 14 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Liraglutide and 16 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Liraglutide and 9 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Dulaglutide and 5 more |
| Fatigue | 7: Semaglutide, Tirzepatide, Dulaglutide, Survodutide and 3 more |
| Abdominal pain | 7: Semaglutide (oral), Tirzepatide, Dulaglutide, Setmelanotide and 3 more |

Model. Individual results vary.
Which retatrutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on retatrutide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is retatrutide’s own.
What the retatrutide safety notes say
The library’s safety note
In the Phase 2 obesity trial (Jastreboff et al., NEJM 2023), the most common adverse events were gastrointestinal: dose-related, mostly mild to moderate, concentrated during dose escalation and partly eased by a 2 mg rather than a 4 mg start (nausea in up to 60% of people in the 8 mg arm that started at 4 mg and 45% at 12 mg, plus vomiting, diarrhea and constipation). Serious adverse events were about as common as on placebo (10 of 267 on retatrutide vs 3 of 70, the trial's ClinicalTrials.gov results). In phase 3 (TRIUMPH-1, Lilly's topline), stopping for adverse events ran 4.1%, 6.9% and 11.3% at 4, 9 and 12 mg vs 4.9% on placebo. As a triple GIP/GLP-1/glucagon agonist it raised resting heart rate in a dose-dependent way; the rise peaked at week 24 and eased after. As a GLP-1-class agent it carries the class rodent thyroid C-cell signal and trial-monitored gallbladder/pancreatitis considerations. These are trial findings, not personal predictions — discuss with your clinician.
The library’s interaction note
As a GLP-1-class agent retatrutide slows gastric emptying, which can alter absorption of oral medications — a published, label-level consideration for the class; discuss timing of oral drugs with your clinician. Combined with insulin or sulfonylureas the additive glucose-lowering effect raises hypoglycemia risk in the class, warranting clinician-guided monitoring. Its glucagon-driven heart-rate effect is a noted consideration alongside sympathomimetics or in pre-existing tachyarrhythmia. No specific interaction data with SSRIs or anticoagulants beyond general clinical caution.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the retatrutide reports come from
The library rates the evidence on retatrutide as established: clinical trials or FDA-approved use exist.
Of the library’s 10 research notes on retatrutide, 7 rest on randomized trials, 2 on clinical data and 1 on community reports.
Our 16 study pages on retatrutide: 1 animal study (mice and hamsters), 3 animal studies (mice), 8 randomized trials, 2 meta-analyses and 2 clinical trials.
So retatrutide has controlled trials in people to set its listed effects against.
What our retatrutide study pages report on safety
Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1
Randomized trial, human, 2026: The most common side effects were mostly mild to moderate stomach and gut problems that eased over time; 2-5% on retatrutide and 0% on placebo stopped treatment because of side effects, no severe low blood sugar was seen, and the 2 deaths, both in the 4 mg arm, were judged unrelated to the drug.
Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1
Randomized trial, human, 2026: Stomach and gut side effects were the most common.
Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetes
Randomized trial, human, 2025: Adverse events were similar across groups, stomach and gut effects were the most common, and no one died.
Retatrutide: top odds of 15% or more weight loss across 19 trials
Meta-analysis, human, 2025: retatrutide also carried the highest risk of side effects.
Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg arm
Randomized trial, human, 2023: Stomach and gut side effects were the most common, rose with dose, were mostly mild to moderate and were partly eased by starting at 2 mg instead of 4 mg. This was a mid-stage trial of 338 people lasting 48 weeks, so it doesn't show longer-term results or rarer side effects.
Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeks
Randomized trial, human, 2022: Side effects that started during treatment affected 33 (63%) people on retatrutide, 60% of those on dulaglutide and 54% of those on placebo, and stomach and gut problems were the most common. This was a small, 12-week early-phase trial built mainly to check safety, with small groups at each retatrutide dose and 29 people leaving the study early.
Questions people ask
What are the side effects of retatrutide?
The side effects most commonly reported for retatrutide are nausea, vomiting and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do retatrutide’s side effects come from human studies?
The library rates the evidence on retatrutide as established, and the library’s evidence on it includes controlled trials in people.
Which retatrutide side effects are its own?
None: each effect the library lists for retatrutide is listed for at least one other metabolic & GLP-1 compound too.
Does retatrutide interact with other medicines?
The library’s interaction note on retatrutide begins: As a GLP-1-class agent retatrutide slows gastric emptying, which can alter absorption of oral medications — a published, label-level consideration for the class; discuss timing of oral drugs with your clinician.